Remedy Entertainment Oyj (HEL:REMEDY)

Remedy Entertainment Oyj Statistics

Total Valuation

HEL:REMEDY has a market cap or net worth of EUR 224.84 million. The enterprise value is 205.62 million.

Market Cap	224.84M
Enterprise Value	205.62M

Important Dates

The next estimated earnings date is Tuesday, February 10, 2026.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	n/a

Share Statistics

HEL:REMEDY has 13.63 million shares outstanding. The number of shares has increased by 0.53% in one year.

Current Share Class	13.63M
Shares Outstanding	13.63M
Shares Change (YoY)	+0.53%
Shares Change (QoQ)	-4.30%
Owned by Insiders (%)	45.01%
Owned by Institutions (%)	8.32%
Float	5.49M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.15
PB Ratio	3.98
P/TBV Ratio	4.62
P/FCF Ratio	16.85
P/OCF Ratio	33.81
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-14.00
EV / Sales	3.80
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	15.41

Financial Position

The company has a current ratio of 3.14, with a Debt / Equity ratio of 0.31.

Current Ratio	3.14
Quick Ratio	3.14
Debt / Equity	0.31
Debt / EBITDA	n/a
Debt / FCF	1.30
Interest Coverage	-9.91

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-23.05%
Revenue Per Employee	138,414
Profits Per Employee	-37,575
Employee Count	367
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	-2.82M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +14.42% in the last 52 weeks. The beta is 1.05, so HEL:REMEDY's price volatility has been similar to the market average.

Beta (5Y)	1.05
52-Week Price Change	+14.42%
50-Day Moving Average	13.59
200-Day Moving Average	14.82
Relative Strength Index (RSI)	74.61
Average Volume (20 Days)	8,954

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HEL:REMEDY had revenue of EUR 54.12 million and -14.69 million in losses. Loss per share was -1.08.

Revenue	54.12M
Gross Profit	41.89M
Operating Income	-16.98M
Pretax Income	-17.52M
Net Income	-14.69M
EBITDA	-14.22M
EBIT	-16.98M
Loss Per Share	-1.08

Balance Sheet

The company has 36.52 million in cash and 17.30 million in debt, giving a net cash position of 19.22 million or 1.41 per share.

Cash & Cash Equivalents	36.52M
Total Debt	17.30M
Net Cash	19.22M
Net Cash Per Share	1.41
Equity (Book Value)	56.56M
Book Value Per Share	4.15
Working Capital	30.57M

Cash Flow

In the last 12 months, operating cash flow was 6.65 million and capital expenditures 6.70 million, giving a free cash flow of 13.35 million.

Operating Cash Flow	6.65M
Capital Expenditures	6.70M
Free Cash Flow	13.35M
FCF Per Share	0.98

Margins

Gross margin is 77.39%, with operating and profit margins of -31.37% and -27.15%.

Gross Margin	77.39%
Operating Margin	-31.37%
Pretax Margin	-32.36%
Profit Margin	-27.15%
EBITDA Margin	-26.27%
EBIT Margin	-31.37%
FCF Margin	24.66%

Dividends & Yields

HEL:REMEDY does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.53%
Shareholder Yield	-0.53%
Earnings Yield	-6.53%
FCF Yield	5.94%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

HEL:REMEDY has an Altman Z-Score of 4.21 and a Piotroski F-Score of 3.

Altman Z-Score	4.21
Piotroski F-Score	3